Kidney CalculiNCT02434068
Assessment of Flexible Ureteroscopy Residual Fragments
An observational study of Kidney Calculi, run by University of Sao Paulo General Hospital at 1 site in Brazil.
Trial summary
Residual fragments of urinary calculi after flexible ureteroscopy (URF) can cause symptoms and additional surgeries. The assessment of residual fragments by imaging is not standardized. Computed tomography (CT) is the best way for evaluation of urinary stones, however, ionizing radiation from CT is deleterious. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Calculi
- What is being tested?
- CT
- How many people
- 115 participants
- Where
- 1 siteBrazil
- Study dates
- Mar 2015to Jul 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with symptomatic renal calculi
Who may be able to join
- Kidney calculi > 5 mm and < 20 mm or < 15 mm in lower kidney calyx
Who cannot join
- Patients with kidney malformations, ureteral stenosis, previous ipsilateral kidney surgery, hydronephrosis, indwelling double J stent and contraindications for URF are going to be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Residual fragments of urinary calculi after flexible ureteroscopy (URF) can cause symptoms and additional surgeries. The assessment of residual fragments by imaging is not standardized. Computed tomography (CT) is the best way for evaluation of urinary stones, however, ionizing radiation from CT is deleterious. The aim of this study is to define which patients may avoid CT for evaluation of residual fragments after URF. 115 patients with > 18 years old undergoing URF for kidney stone < 20 mm or < 15 mm in the lower calyx diagnosed by CT will be studied. The clinical evaluation of patients will be held by the same urologist in pre-operative consultation, 7 days after the procedure, 30 days after the procedure and 100 days after the procedure. The assessment of residual fragments will be made through TC, ultrasound and Kidney-bladder-ureter KUB 90 days after the procedure. The image methods for residual fragments assessment will be compared by Cochran Test and prediction of parameters to avoid CT will be made by multiple logistic regression, using IPSS 16.0, with significant level of 5%.
Read the detailed description
Flexible ureteroscopy (URF) is being widely used for the treatment of kidney stones up to 20 mm. The assessment of residual fragments must be done because they could cause pain and additional surgical interventions. However, nor the timing or modality of image study for this assessment is standardized yet.
Computed Tomography (CT) has become the standard for diagnosing urinary stones. Stone-former patients are submitted to many CT studies during life due to stone-related events. However, the cumulative exposure to the ionizing radiation of CT may induce tumors. Therefore, efforts to reduce radiation exposure are recommended such as better selection of the timing to submit the patient to CT, low radiation dose protocols and restriction of body region to be examined.
Up to 38% of the patients have residual fragments more than 2 mm assessed by CT after URF. The investigators goal is to predict witch patients should be submitted to CT for the assessment of residual fragments after URF and to evaluate the clinical significance of residual fragments and URF complications.
Method
115 consecutive symptomatic adult (>18 years-old) patients diagnosed by CT with kidney stone more than 5 mm and less than 20 mm or less than 15 mm in inferior calyx are going to be submitted to URF. Residual fragments are going to be assessed by CT, ultrasound and plain radiography during post-operative period. The study protocol is approved by our hospital's ethics committee, and written informed consent is going to be obtained from all patients according to the Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects.
Sample size
Sample size was calculated based on the percentage of patients with residual fragments more than 2 mm by CT of 38% and by plain radiography of 17%. Therefore, sample size for a bicaudal test with significance level of 5% and test power of 95% is 115 subjects.
Exclusion factors
Patients with kidney malformations, ureteral stenosis, previous ipsilateral kidney surgery, hydronephrosis, indwelling double J stent and contraindications for URF are going to be excluded.
Flexible ureteroscopy
The procedure is going to be performed in a radiation proof operating room under general anesthesia.
A pyelography is obtained and a Nitinol 0.035" guidewire and a PTFE 0.035" guidewire are inserted up to the renal pelvis under radioscopy guidance.
Semi-rigid ureteroscopy is performed for active dilation of the ureter. Ureteral sheath 10/12F x 35 cm is than placed up to the upper ureter and the flexible ureteroscope is inserted through the ureteral sheath for direct identification of all renal calices and kidney stones before lithotripsy.
Laser lithotripsy will be performed with a 200-270 micron Holmium laser fiber until complete stone dusting or basketing of stone fragments > 2 mm with < 1.9 F tipless basket. Stone fragments < 2 mm are acceptable. Pyelography through ureteral sheath will be done to search for perforation of the urinary tract and to help proper positioning of 6 F double J stent in the renal pelvis. The ureteral sheath is going to be removed under direct ureteroscopic vision to care for ureteral lesions and ureteral stone fragments.
Follow-up
The clinical evaluation will be held by the same urologist in pre-operative consultation, 7 days after the procedure, 30 days after the procedure and 100 days after the procedure. The assessment of residual fragments will bem ade through CT, urinary tract Ultrasound (US) and X-Ray of the abdomen (Rx) in 90 days postoperatively in all patients. After the procedure, patients receive guidelines and prescribing for household use standardized pain control.
Evaluated parameters
The parameters evaluated in each patient will be: demographic data like gender, age, race, body mass index, waist circumference, kidney stone size with 3 measures diameters for calculation of maximum diameter, area and volume, measured in Hounsfield units of kidney stone, number of stones, position of the stone in the kidney, kind of ureteroscope used, operative time measured from the beginning of the cystoscopy to withdrawal of all endoscopic equipments and from start to finish the insertion of the flexible ureteroscope into the kidney, lithotripsy technique (basketing without fragmentation, dusting or combined technique), endoscopic inspection at the end and presence of residual fragments > 2 mm in postoperative CT, composition of urinary calculi, 2 blood and urinary metabolic evaluations of each patient to be made between 45 and 90 days of the procedure, including: total calcium, parathyroid hormone (PTH), uric acid, urea, creatinine, venous blood gas, urine pH, urine culture, 24 hours urine dosage of calcium, sodium, citrate, oxalate, cystine, creatinine, urea, uric acid and phosphate. Other authors (8) demonstrated in a retrospective study that the size of the stone (p < 0.001), location (p< 0.001), multiplicity (p = 0.003), surgical time (p = 0.008) and exclusive use of flexible ureteroscope (p = 0.029) are associated with the presence of residual fragments.
Sensitivity and specificity of the combination US + Rx for identification of residual fragments on postoperative CT, predictive parameters for the best accuracy of the combination US + Rx and endoscopic end inspection and the occurence of complications such as ureteral lesion, renal dilatation, visits to the emergency room for pain control, need for additional procedures are going to be determined.
Statistics
The comparison between the methods of assessment of residual fragments will be done with Cochran test and prediction of parameters to avoid CT will be made with multiple logistic regression, using the IPSS 16.0 program, with a significance level of 5%.
- Conditions
- Kidney Calculi
- Being tested
- CT
- Keywords
- kidney calculi, followup studies
- Medical subject headings
- Kidney Calculi
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CTOther
Also called US, KUB
followup
| Study group | Role | What they receive |
|---|---|---|
| stone residuals | all patients are going to be submitted to the same intervention: CT, US, KUB Receives: Other: CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
residual calculi > 2mm by CT
Measured: 90 days
Secondary outcomes (1)
complications by CT
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2015 (estimated)
- Study startMar 2015
- Primary completionMar 2017 (estimated)
- Study completionJul 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney CalculiStudies of the same condition, open and under way.
- More trials run by University of Sao Paulo General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 115 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Sao Paulo General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Responsible party
- Sponsor
- Investigators
- Alexandre Danilovic, MD, Principal investigator, University of Sao Paulo General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02434068
- Sponsor's protocol ID
- 11851
- Status last verified
- Oct 2016
- First submitted
- 19 Feb 2015
- Last updated
- 28 Oct 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Flexible Ureteroscopy Residual Fragments
- ClinicalTrials.gov ID
- NCT02434068
- Acronym / sponsor ID
- 11851
- Conditions
- Kidney Calculi
- Keywords
- kidney calculi, followup studies
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 115 participants (estimated)
- Lead sponsor
- University of Sao Paulo General HospitalUniversity, hospital or other
- Collaborators
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Study start
- Mar 2015
- Primary completion
- Mar 2017 (estimated)
- Study completion
- Jul 2017 (estimated)
- First posted
- 5 May 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Residual fragments of urinary calculi after flexible ureteroscopy (URF) can cause symptoms and additional surgeries. The assessment of residual fragments by imaging is not standardized. Computed tomography (CT) is the best way for evaluation of urinary stones, however, ionizing radiation from CT is deleterious. The aim of this study is to define which patients may avoid CT for evaluation of residual fragments after URF. 115 patients with > 18 years old undergoing URF for kidney stone < 20 mm or < 15 mm in the lower calyx diagnosed by CT will be studied. The clinical evaluation of patients will be held by the same urologist in pre-operative consultation, 7 days after the procedure, 30 days after the procedure and 100 days after the procedure. The assessment of residual fragments will be made through TC, ultrasound and Kidney-bladder-ureter KUB 90 days after the procedure. The image methods for residual fragments assessment will be compared by Cochran Test and prediction of parameters to avoid CT will be made by multiple logistic regression, using IPSS 16.0, with significant level of 5%.
Detailed description
Flexible ureteroscopy (URF) is being widely used for the treatment of kidney stones up to 20 mm. The assessment of residual fragments must be done because they could cause pain and additional surgical interventions. However, nor the timing or modality of image study for this assessment is standardized yet.
Computed Tomography (CT) has become the standard for diagnosing urinary stones. Stone-former patients are submitted to many CT studies during life due to stone-related events. However, the cumulative exposure to the ionizing radiation of CT may induce tumors. Therefore, efforts to reduce radiation exposure are recommended such as better selection of the timing to submit the patient to CT, low radiation dose protocols and restriction of body region to be examined.
Up to 38% of the patients have residual fragments more than 2 mm assessed by CT after URF. The investigators goal is to predict witch patients should be submitted to CT for the assessment of residual fragments after URF and to evaluate the clinical significance of residual fragments and URF complications.
Method
115 consecutive symptomatic adult (>18 years-old) patients diagnosed by CT with kidney stone more than 5 mm and less than 20 mm or less than 15 mm in inferior calyx are going to be submitted to URF. Residual fragments are going to be assessed by CT, ultrasound and plain radiography during post-operative period. The study protocol is approved by our hospital's ethics committee, and written informed consent is going to be obtained from all patients according to the Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects.
Sample size
Sample size was calculated based on the percentage of patients with residual fragments more than 2 mm by CT of 38% and by plain radiography of 17%. Therefore, sample size for a bicaudal test with significance level of 5% and test power of 95% is 115 subjects.
Exclusion factors
Patients with kidney malformations, ureteral stenosis, previous ipsilateral kidney surgery, hydronephrosis, indwelling double J stent and contraindications for URF are going to be excluded.
Flexible ureteroscopy
The procedure is going to be performed in a radiation proof operating room under general anesthesia.
A pyelography is obtained and a Nitinol 0.035" guidewire and a PTFE 0.035" guidewire are inserted up to the renal pelvis under radioscopy guidance.
Semi-rigid ureteroscopy is performed for active dilation of the ureter. Ureteral sheath 10/12F x 35 cm is than placed up to the upper ureter and the flexible ureteroscope is inserted through the ureteral sheath for direct identification of all renal calices and kidney stones before lithotripsy.
Laser lithotripsy will be performed with a 200-270 micron Holmium laser fiber until complete stone dusting or basketing of stone fragments > 2 mm with < 1.9 F tipless basket. Stone fragments < 2 mm are acceptable. Pyelography through ureteral sheath will be done to search for perforation of the urinary tract and to help proper positioning of 6 F double J stent in the renal pelvis. The ureteral sheath is going to be removed under direct ureteroscopic vision to care for ureteral lesions and ureteral stone fragments.
Follow-up
The clinical evaluation will be held by the same urologist in pre-operative consultation, 7 days after the procedure, 30 days after the procedure and 100 days after the procedure. The assessment of residual fragments will bem ade through CT, urinary tract Ultrasound (US) and X-Ray of the abdomen (Rx) in 90 days postoperatively in all patients. After the procedure, patients receive guidelines and prescribing for household use standardized pain control.
Evaluated parameters
The parameters evaluated in each patient will be: demographic data like gender, age, race, body mass index, waist circumference, kidney stone size with 3 measures diameters for calculation of maximum diameter, area and volume, measured in Hounsfield units of kidney stone, number of stones, position of the stone in the kidney, kind of ureteroscope used, operative time measured from the beginning of the cystoscopy to withdrawal of all endoscopic equipments and from start to finish the insertion of the flexible ureteroscope into the kidney, lithotripsy technique (basketing without fragmentation, dusting or combined technique), endoscopic inspection at the end and presence of residual fragments > 2 mm in postoperative CT, composition of urinary calculi, 2 blood and urinary metabolic evaluations of each patient to be made between 45 and 90 days of the procedure, including: total calcium, parathyroid hormone (PTH), uric acid, urea, creatinine, venous blood gas, urine pH, urine culture, 24 hours urine dosage of calcium, sodium, citrate, oxalate, cystine, creatinine, urea, uric acid and phosphate. Other authors (8) demonstrated in a retrospective study that the size of the stone (p < 0.001), location (p< 0.001), multiplicity (p = 0.003), surgical time (p = 0.008) and exclusive use of flexible ureteroscope (p = 0.029) are associated with the presence of residual fragments.
Sensitivity and specificity of the combination US + Rx for identification of residual fragments on postoperative CT, predictive parameters for the best accuracy of the combination US + Rx and endoscopic end inspection and the occurence of complications such as ureteral lesion, renal dilatation, visits to the emergency room for pain control, need for additional procedures are going to be determined.
Statistics
The comparison between the methods of assessment of residual fragments will be done with Cochran test and prediction of parameters to avoid CT will be made with multiple logistic regression, using the IPSS 16.0 program, with a significance level of 5%.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| stone residuals | – | Other: CTall patients are going to be submitted to the same intervention: CT, US, KUB |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with symptomatic renal calculi
Key inclusion criteria (1 listed)
- Kidney calculi > 5 mm and < 20 mm or < 15 mm in lower kidney calyx
Key exclusion criteria (1 listed)
- Patients with kidney malformations, ureteral stenosis, previous ipsilateral kidney surgery, hydronephrosis, indwelling double J stent and contraindications for URF are going to be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CTAlso: US, KUBfollowup | Other | stone residuals |
Primary outcome
residual calculi > 2mm by CT
Time frame: 90 days
1 secondary outcome
complications by CT
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Calculi
RecruitingObservational study
Stone Clearance With Aspiration vs Other Technologies: a Real-world Evidence Study
Urolithiasis, Stones, Kidney
Not yet recruiting
Intertransverse Process Block Versus Erector Spinae Plane Block for Postoperative Analgesia After Percutaneous Nephrolithotomy
Kidney Stones, Urolithiasis, Hypocitraturia, Pain, Postoperative
Not yet recruiting
Comparison of Smart Pressure-Controlled Flexible Ureteroscopy and Flexible Suction Ureteral Access Sheath-Assisted Flexible Ureteroscopy for 2-3 cm Renal Stones
Kidney Stones
Not yet recruitingEarly Phase 1
Phosphate & Kidney Stones
Kidney Stones, Calcium Oxalate Kidney Stones
Recruiting
Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology
Urolithiasis, Stones, Kidney
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandre Danilovic, MD principal investigator
University of Sao Paulo General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Calculi, run by University of Sao Paulo General Hospital at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
residual calculi > 2mm by CT (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2016; AzTrials last refreshed its copy on 7 Nov 2026.